Bausch Health Companies Inc. and its aesthetics business Solta Medical announced the availability of Fraxel FTX in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners starting 1 September 2026. Fraxel FTX, the next generation of the Fraxel platform, builds on over 20 years of innovation, featuring dual wavelengths for targeted treatment at different tissue depths, Intelligent Optical Tracking with AccuTRAC, a redesigned ergonomic handpiece with a 20% reduction in circumference and weight, and integrated cooling for patient comfort. The system is designed to address common skin concerns including fine lines, wrinkles, lentigos, acne scars, surgical scars, dyschromia including melasma, and actinic keratosis. Solta Medical will support practitioners with clinical education, practical training, and business support in Australia and New Zealand.
Bausch Health Companies IncLaunch of new Fraxel FTX product in Australia expands its technology portfolio and market reach.
